FDA Extends Review of Belite Bio’s Tinlarebant for Stargardt Disease to May 2027
The FDA has extended its review of Belite Bio’s tinlarebant for Stargardt disease by three months. New PDUFA date is May 12, 2027.
Already have an account? Sign in.